anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention is a feed supplement consisting of a blood product from at least one Crocodylian species such as the American alligator ( Alligator mississippiensis ). The blood product is whole blood, hemolyzed blood, serum or plasma. The feed supplement is a liquid or solid. The feed supplement may be combined with a high nutrient feed or starter diet. The feed composition may contain 0.1% or more by weight of the feed supplement. The feed supplement is fed to weanling pigs or poultry hatchlings to increase their weight and feed intake. It is also expected to promote gut health.
A wound treatment composition comprises honey and a gelling agent. The honey and the gelling agent are dispersed in water. The wound treatment composition forms a gel on contact with wound exudate. The honey may be produced nectar from plants of the genus Leptospermum, such as manuka honey and jelly bush honey. The gelling agent is an alginate or pectin, for example, sodium alginate. The wound treatment composition may further comprise one or more additional agents selected from antimicrobial agents, antiseptic agents, antifungal agents, anti-inflammatory agents, vitamins and/or minerals. These can include polyhexamethylene biguanide (PHMB) and manuka oil. The wound treatment compostion is produced by dispersing the gelling agent in water and adding the water/gelling agent mixture to honey. The honey may be warmed prior to the addition of the water/gelling agent mixture. An additional antimicrobial agent may also be added to the water and/or the honey prior to mixing. The wound treatment composition can be provided in a kit with a secondary dressing. The secondary dressing may be an air and moisture vapour-permeable plastic film, such as polyurethane.
There is a vast spectrum of clinical manifestations encountered in individuals with lysosomal storage diseases. Lysosomal storage disorders occur when an enzyme necessary for breaking down intracellular fats, proteins, recycled products and organelles in the cell is deficient. As a result, substrate accumulates within the lysosomes affecting different organ systems. The most common lysosomal storage disease, Gaucher disease (GD), results from the inherited deficiency of the enzyme glucocerebrosidase, which breaks down the lipid glucocerebroside. The disease is characterized by extremely variable manifestations, with some patients presenting in childhood with hepatosplenomegaly, anemia, thrombocytopenia and bony problems, some in infancy with a lethal neurodegenerative course, while others remain asymptomatic into their eighth decade. GD has traditionally been divided into three clinical subtypes, type 1 (non-neuronopathic), type 2 (acute neuronopathic), and type 3 (chronic neuronopathic) delineated by the absence or presence of neurologic involvement and its rate of progression. Some patients, however, defy classification into these three categories, and it may be more accurate to regard GD as a continuum of phenotypes. In addition, patients and carriers of mutations in GBA1, the gene for GD, are at increased risk for developing Parkinson disease (PD) and related neurodegenerative disorders.

This is a longitudinal natural history study of patients with lysosomal storage disorders with emphasis on phenotypic heterogeneity of GD and those at risk for the development of parkinsonism. Our goal is to identify genetic, biochemical, and clinical parameters that are associated with disease severity in individuals with lysosomal storage disorders to identify individuals with milder or early phenotypic manifestations, and to explore the natural history and extent of associated clinical manifestations. We also study subjects with GBA1 mutations who are at higher risk for developing parkinsonism to identify early disease manifestations and potential biomarkers. Participants are evaluated at the NIH to better characterize the clinical, genetic and pathophysiological features of these disorders. In order to better understand the entire effect of the enzyme deficiencies and the function of the specific proteins involved, emphasis is placed on individuals with atypical presentations. In particular, we will focus on subjects with GD and PD, to better understand the association between the two disorders. Following an initial comprehensive workup, participants will be studied either in the inpatient wards or the outpatient clinic and will be re-evaluated at periodic intervals longitudinally.
### Invasive aspergillosis and serious fungal infections due to Fusarium spp. and Scedosporium apiospermum

See Table 1. Therapy must be initiated with the specified loading dose regimen of intravenous voriconazole on Day 1 followed by the recommended maintenance dose regimen. Intravenous treatment should be continued for at least 7 days. Once the patient has clinically improved and can tolerate medication given by mouth, the oral tablet form or oral suspension form of voriconazole may be utilized. The recommended oral maintenance dose of 200 mg achieves a voriconazole exposure similar to 3 mg/kg IV; a 300 mg oral dose achieves an exposure similar to 4 mg/kg IV. Switching between the intravenous and oral formulations is appropriate because of the high bioavailability of the oral formulation in adults [see Clinical Pharmacology (12)]. 

### Candidemia in non-neutropenic patients and other deep tissue Candida infections

See Table 1. Patients should be treated for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer. 

### Esophageal Candidiasis

See Table 1. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.
The comparison group (low intensity) receives access to the e-platform and given an educational package with information about nutrition, physical activity, and smoking based on the NAVIGATE program (Mueser et al., 2015); i.e., a comprehensive program for implementing coordinated speciality care) with weekly e-mail reminders for 12 weeks. Participants receive access to online resources and free online webinars about these healthy behaviours.
PROBLEM TO BE SOLVED: To provide a use of anti-connexin polynucleotides for the treatment of surgical adhesions.SOLUTION: Provided are a connexin modulation for the treatment of surgical adhesions, and associated methods, compositions, and articles. The invention provides a method for preventing or alleviating postoperative adhesions in subjects. This method comprises administering at a surgical site in a patient an effective amount of an anti-connexin polynucleotide. In one embodiment, the anti-connexin polynucleotide is administered at a surgical incision site. In one embodiment, the anti-connexin polynucleotide is administered during surgery and/or after surgery. In one embodiment, the anti-connexin polynucleotide is effective, in whole or in part, to (1) downregulate expression of a connexin protein, (2) inhibit intercellular communication by decreasing gap junction formation, (3) prevent or reduce surgical adhesions at a site of the surgery or surgical repair.
SummaryHereditary haemorrhagic telangiectasia (HHT) has an estimated prevalence of 1 in 5000-8000 individuals globally with pulmonary arteriovenous malformations (PAVMs) affecting approximately 15%-50% of HHT patients. Ischaemic stroke is a known complication of PAVMs that affects ≤30% of patients with PAVMs. Studies have shown that patients with PAVMs have ischaemic stroke a decade earlier than routine stroke. The predominant mechanism of ischaemic stroke in HHT patients is paradoxical embolism due to PAVMs, but most HHT-related PAVMs are asymptomatic. Additionally, HHT is often underdiagnosed in patients and poses a challenge to physicians due to its rarity. We present a case of a patient with ischaemic stroke who was subsequently diagnosed with HHT and found to have a PAVM on further evaluation. This case highlights the importance of using an individualised patient-centred stroke evaluation and screening for PAVMs in patients who had a stroke with possible or suspected HHT and definite HHT.
Formation of adhesions, which is a process in which adjacent tissues or organs bind to each other, can be caused by infections, inflammation diseases, surgery procedures or trauma. Following abdominal surgery, the incidence of the formation of adhesions may be as high as 90%. Pain, discomfort, immobility and retarded wound healing are common complications due to adhesions formation; moreover, depending on the tissues involved, adhesions can cause various disorders. In the eye, adhesion of the iris to the lens can lead to glaucoma. In the intestines, adhesions can cause partial or complete bowel obstruction which is life threatening. Intrauterine adhesions are known as the Asherman syndrome. Pelvic adhesions can lead to infertility and reproductive problems. Problems associated with adhesions often require a further operative procedure in order to remove the adhesions. This could have the major drawback of leading to new adhesion formation. A wide variety of adjunctive treatments have been investigated to reduce or prevent post surgical adhesions. Most of these treatments, however, show inconsistent results. In an attempt to reduce the inflammatory reaction at the wounded site following surgery, the use of corticosteroids, NSAIDS, histamine antagonists and calcium channel blockers have been investigated. More recently, barrier materials have been suggested for the prevention of post surgical adhesions. These include, but are not limited to, Hyskon®, Ringer's lactate, Interceed® (oxidized regenerated cellulose), Polaxamer 407® (temperature dependent polymer), Gore-Tex® (expanded polytetrafluorethylene) and SepraFilm® (hyaluronic acid derivative film).
PURPOSE OF REVIEW: This review examines the linked pathophysiology of Alzheimer's disease/related dementia (AD/ADRD) and bone disorders like osteoporosis. The emphasis is on "inflammaging"-a low-level inflammation common to both, and its implications in an aging population.
RECENT FINDINGS: Aging intensifies both ADRD and bone deterioration. Notably, ADRD patients have a heightened fracture risk, impacting morbidity and mortality, though it is uncertain if fractures worsen ADRD. Therapeutically, agents targeting inflammation pathways, especially Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and TNF-α, appear beneficial for both conditions. Additionally, treatments like Sirtuin 1 (SIRT-1), known for anti-inflammatory and neuroprotective properties, are gaining attention. The interconnectedness of AD/ADRD and bone health necessitates a unified treatment approach. By addressing shared mechanisms, we can potentially transform therapeutic strategies, enriching our understanding and refining care in our aging society. This review article is part of a series of multiple manuscripts designed to determine the utility of using artificial intelligence for writing scientific reviews.
Some embodiments provide a program that receives a set of words. The program further determines an embedding for a word in the set of words. The program also accesses a knowledge base to retrieve a plurality of entries. Each entry includes a text description of a concept. The program further determines, for each entry in the plurality of entries in the knowledge base, an embedding for the entry based on the text description of the concept. The program also calculates, for each entry in the plurality of entries in the knowledge base, a distance value between the embedding for the word in the set of words and the embedding for the entry. The program further determines an entry in the plurality of entries in the knowledge base having a text description of a concept that best represents the set of words based on the plurality of distance values.
BACKGROUND: The primary objective of this study was to investigate the diagnostic characteristics of bone scintigraphy single-photon emission computed tomography/computed tomography (BS-SPECT/CT) for diagnosing aseptic loosening after uncemented total knee arthroplasty (TKA), and to evaluate the following aspects: how to manage inconclusive results, the interobserver reliability, and the location of tracer uptake between symptomatic cases with and without aseptic loosening.
METHODS: In this study, 180 patients who had uncemented TKA and persistent knee pain suspected of aseptic loosening were included. As part of routine medical care, BS-SPECT/CT was used, and its results were compared with the reference standard, which involved revision surgery for aseptic loosening or a 12-month follow-up without revision or imaging. Inconclusive BS-SPECT/CT results were considered either negative (best-case scenario) or positive (worst-case scenario). Sensitivity, specificity, positive/negative likelihood ratios (LRs), and positive/negative predictive values (PPV and NPV) were calculated. Sensitivity analyses were conducted by comparing the diagnostic characteristics between cases with a follow-up of less and more than 2 years of follow-up. The anatomical distribution of tracer uptake and interobserver reliability were also evaluated.
RESULTS: Of the 180 BS-SPECT/CT scans conducted, 22 were determined positive, 113 negative, and 45 inconclusive. The best-case scenario showed a sensitivity of 66.7%, specificity of 93.8%, +LR 10.8, -LR 0.4, PPV 54.6%, and NPV 96.2%. In contrast, the worst-case scenario had a sensitivity of 94.4%, specificity of 69.1%, +LR 3.1, -LR 0.1, PPV 25.4%, and NPV 99.1%. Sensitivity analyses revealed no relevant differences in characteristics between the 2 TKA-interval groups. The interobserver reliability was fair-to-moderate (κ = 0.39; 95% confidence interval 0.18 to 0.60), with an estimated agreement of 79% (95% confidence interval 70 to 87). Four prosthetic zones had a notably higher proportion of cases with tracer uptake in those with aseptic loosening compared to those without.
CONCLUSIONS: The test characteristics of BS-SPECT/CT were deemed appropriate in patients who have complaints of uncemented TKA suspected of aseptic loosening. Inconclusive cases were best categorized as negative, especially in patients who have a short interval between TKA and the first BS-SPECT/CT. Increased tracer uptake in 4 prosthetic zones was observed in cases of aseptic loosening, although interobserver reliability was fair to moderate.
LEVEL OF EVIDENCE: Level III, Diagnostic Retrospective Cohort Study.
The aim of this study was to investigate the effect of trunk position and experimental lumbar pain location on lumbar extensor muscle recruitment strategies. Nineteen healthy participants (10 men and 9 women), aged 25.3 ± 4.7 yr, performed isometric back extension contractions in three positions (neutral, 45°, and 90° trunk flexion) and under three conditions (no pain, caudal pain, and cranial pain). Lumbar muscle activation strategies were recorded using high-density surface electromyography. The effect of position and pain condition on muscle activity amplitude and spatial redistributions was assessed. Muscle activity amplitude was 43% higher in 45° trunk flexion than in neutral position on both sides (P < 0.05). In the 90° trunk flexion, participants showed a more lateral spatial distribution than in the 45° trunk flexion on the left side (P < 0.01, 5.4 mm difference) and the neutral position on both sides (P < 0.05, 8.2 mm difference). In the 45° trunk flexion, participants exhibited a more lateral spatial distribution compared with the neutral position on the right side (P < 0.05, 3.7 mm difference). A lateral spatial redistribution of muscle activity was observed in the caudal pain condition compared with the no pain condition on the right side (P < 0.05, 3.0 mm difference). Individual responses to pain varied across all variables. Different trunk positions result in different distributions of activation within the lumbar extensor muscles, possibly based on regional mechanical advantage. No clear indication of location-specific pain adaptation and no effect of task-dependent pain adaptation were found, whereas individual-specific adaptations were observed.NEW & NOTEWORTHY Changes in muscle activity amplitude and spatial redistribution of lumbar extensor muscles were observed in different trunk positions, potentially due to changes in their mechanical advantage. The results complement the current pain-adaptation theory by illustrating individual spatial redistributions of activation within lumbar extensor muscles during pain. The study found no clear indication of location-specific pain adaptation and no effect of task-dependent pain adaptation.
Korean American immigrants (KAI), one of the most underserved and understudied minority populations in the U.S., suffer from diabetes, which goes under-diagnosed, inadequately treated and has a potential to result in costly and tragic consequences. Language barriers, the lack of self-confidence, and diminished social support that accompany the acculturation process prevent KAI from improving their health-seeking behaviors. Our previous research has indicated that overwhelming numbers of KAI suffer not only from uncontrolled hyperglycemia but also from a loss of self-confidence and social isolation because of language and cultural barriers. They are in urgent need of an intervention to assist them in their efforts to achieve better glycemic control and restore their self-confidence in diabetes and health management so that they are able to adjust successfully in this new environment. Therefore, The purpose of this study is to assess the feasibility and efficacy of a culturally-tailored, comprehensive behavioral intervention program specially designed for linguistically challenged KAIs with type 2 DM.

This pilot project will test the hypothesis: Compared to KAI in the control group, KAI with type 2 DM who receive a comprehensive DM management intervention through structured psycho-behavioral education, home glucose monitoring with a telephone transmission system, and interaction with a bilingual nurse case manager will show: (1) a greater level of glucose control; and (2) a greater level of self-help skills including knowledge related to glucose control, problem-solving skills, heightened confidence and mood/affect, adherence to treatment recommendations, and quality of life. An additional outcome will be to measure and obtain an ideal BP as the proposed intervention focuses on management of multiple risk factors with which many KA DM patients often struggle.
Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises. In addition, Diet will be recommended by the doctor as routine treatment.
A mobility augmentation system assists a user's movement by determining a corresponding electrical stimulation for the movement. A wearable stimulation array includes sensors, electrodes, an electrode multiplexer, and a controller that executes the mobility augmentation system. The sensors measure movement data, and the mobility augmentation system applies a movement model to the measured movement data. The model can determine different electrical actuation instructions depending on the movement stimulated. For example, to stimulate a knee flexion, the movement model output enables a first set of the electrodes to operate as cathodes and a second set of electrodes to operate as anodes. To stimulate a knee extension, the first set of electrodes can be enabled to operate as anodes and a third set of electrodes as cathodes. The user can provide feedback of the applied stimulation, which the system can use to retrain the model and optimize the stimulation to the user.
This is an experimental, prospective, unblinded, randomized, comparative clinical trial between patients with two types of prosthetic implants (inverted arthroplasty with medialized center of rotation vs inverted arthroplasty with lateralized center of rotation). Those male or female patients who meet the inclusion criteria will be selected to form part of one of the two randomly distributed study groups. Sample size Based on studies with similar characteristics but where lateralization is not performed with the implant but with a bone graft would require a sample size of 34 patients (17 in each group) assuming 20% losses with a Type I error of 0. 05 and a statistical power of 80% to show a difference of 10 points on the Constant scale (the minimal clinically important difference on the Constant scale for reverse arthroplasty is described as 8 points in previous comparative studies so we consider the detection of a difference of 10 to be sufficient. The minimal clinically important difference for function and strength in patients undergoing reverse shoulder arthroplasty. The final N needed would be 42 patients (21 per group). A randomization of patients will be performed to assign them to one or the other study group, which will be carried out by an independent assistant, who will generate a random sequence that will be unknown to the investigators. Each patient will be given a sealed and numbered envelope to choose from, in which the randomized group in which he/she has been included will be determined. The study will be blinded for the patient and rehabilitator but not for the surgeon.
The control group will receive "placebo" type procedures in addition to the usual medical rehabilitation procedures, i.e., heat treatments, so routine health care will not be lost. The typical procedures are assigned in accordance with the order of the Minister of Health of the Republic of Lithuania "On the approval of descriptions of general and special requirements for the provision of medical rehabilitation and anti-recidivism sanatorium treatment services" valid version dated 06.14.2023). In-resort sanatoriums, the mud and mineral water procedures are additionally paid services, which the sanatorium will provide free of charge for scientific development.
PURPOSE: A composition containing mesenchymal stem cells for suppressing immunity is provided to effectively prevent diseases caused by T cell overexpression. CONSTITUTION: A composition for suppressing immune response contains stem cells expressing tryptopane metabolic enzyme genes. The enzyme is kynurenine 3-hydroxylase(KMO) or kynureninase(KYNU). The stem cell is prepared by transduction using recombinant expression vector, pBI-CMV1-KMO-KYNU. The stem cell is adult stem cells. The composition is used for treating and preventing transplantation rejection, auto immune diseases, or chronic inflammatory diseases.